Published in Adv Enzyme Regul on January 01, 2003
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem (2008) 0.90
Tissue-specific expression of ferritin H regulates cellular iron homoeostasis in vivo. Biochem J (2006) 0.89
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Regulation of ferritin genes and protein. Blood (2002) 3.27
Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell (2004) 3.21
Iron and cancer: more ore to be mined. Nat Rev Cancer (2013) 2.40
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci U S A (2010) 1.99
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood (2008) 1.97
Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 1.94
An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res (2011) 1.91
Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging (2013) 1.82
Serum ferritin: Past, present and future. Biochim Biophys Acta (2010) 1.80
Iron chelators in cancer chemotherapy. Curr Top Med Chem (2004) 1.61
TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med (2005) 1.52
Wild-type and mutant p53 proteins interact with mitochondrial caspase-3. Cancer Biol Ther (2011) 1.49
Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev (2009) 1.49
Ferritin for the clinician. Blood Rev (2008) 1.46
Demand for continuing medical education programs on cancer care among primary care physicians in North Carolina. N C Med J (2004) 1.46
Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci U S A (2009) 1.41
Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A (2009) 1.34
Phase II trial of radio frequency ablation of renal cancer: evaluation of the kill zone. J Urol (2002) 1.30
Ironing out cancer. Cancer Res (2011) 1.25
Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem (2002) 1.23
A systems biology view of cancer. Biochim Biophys Acta (2009) 1.17
Iron chelation in the biological activity of curcumin. Free Radic Biol Med (2006) 1.17
The role of iron chelation in cancer therapy. Curr Med Chem (2003) 1.15
Excess capacity of the iron regulatory protein system. J Biol Chem (2007) 1.14
Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol (2009) 1.14
Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode. Breast Cancer Res Treat (2010) 1.14
Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J Neurosci Res (2003) 1.13
Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J (2005) 1.12
The transplant iron score as a predictor of stem cell transplant survival. J Hematol Oncol (2009) 1.10
Bioinformatics tools for cancer metabolomics. Metabolomics (2011) 1.10
Thermal ablation therapeutics based on CN(x) multi-walled nanotubes. Int J Nanomedicine (2007) 1.09
Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. Blood (2005) 1.08
Photothermal response of human and murine cancer cells to multiwalled carbon nanotubes after laser irradiation. Cancer Res (2010) 1.05
Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging (2010) 1.05
BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. J Histochem Cytochem (2009) 1.04
Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res (2009) 1.04
A general map of iron metabolism and tissue-specific subnetworks. Mol Biosyst (2009) 1.02
A human bone morphogenetic protein antagonist is down-regulated in renal cancer. Mol Biol Cell (2007) 1.01
Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res (2005) 1.01
Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol (2008) 1.01
Oxathiolene oxide synthesis via chelation-controlled addition of organometallic reagents to alkynols followed by addition of sulfur electrophiles and evaluation of oxathiolene oxides as anticarcinogenic enzyme inducers. Bioorg Med Chem (2005) 0.98
Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol (2012) 0.98
The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials (2012) 0.97
Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology (2006) 0.97
Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem (2009) 0.94
IRP2 regulates breast tumor growth. Cancer Res (2013) 0.94
Activation of caspase pathways during iron chelator-mediated apoptosis. J Biol Chem (2002) 0.94
Fluorinated graphene oxide; a new multimodal material for biological applications. Adv Mater (2013) 0.93
Development of iron-containing multiwalled carbon nanotubes for MR-guided laser-induced thermotherapy. Nanomedicine (Lond) (2011) 0.92
Serum levels of phytanic acid are associated with prostate cancer risk. Prostate (2005) 0.92
Determinants of the thrombogenic potential of multiwalled carbon nanotubes. Biomaterials (2011) 0.92
Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem (2008) 0.90
Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate (2012) 0.89
Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells. PLoS One (2011) 0.89
Ferritin binds to light chain of human H-kininogen and inhibits kallikrein-mediated bradykinin release. Biochem J (2002) 0.89
SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. Breast Cancer Res Treat (2010) 0.89
Carbon nanotubes in hyperthermia therapy. Adv Drug Deliv Rev (2013) 0.89
Tissue-specific expression of ferritin H regulates cellular iron homoeostasis in vivo. Biochem J (2006) 0.89
Health system correlates of receipt of radiation therapy after breast-conserving surgery: a study of low-income Medicaid-enrolled women. Am J Manag Care (2008) 0.88
Differential gene expression in normal and transformed human mammary epithelial cells in response to oxidative stress. Free Radic Biol Med (2011) 0.88
Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Biochem Pharmacol (2004) 0.88
A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089. Autophagy (2014) 0.88